Stock News

Here’s Why DBV Technologies (DBVT) Stock Collapsed Today

French biopharmaceutical firm DBV Technologies SA’s (DBVT) stock is in a free-fall today. Shares are down nearly 70% after the company voluntarily withdrew …

Here’s Why Tilray (TLRY) Stock Jumped 13% in After-Hours Trading

Shares of Tilray (TLRY) rallied in after-hours trading Tuesday, rising nearly 13%. Driving the medical cannabis maker’s stock was the news that the …

Here’s Why Biocept (BIOC) Stock Skyrocketed 80% Today

It’s a very rewarding trading day for investors in Biocept (BIOC) with shares up nearly 80%, making the stock Wall Street’s bull of …

Proteostasis Therapeutics (PTI) Sparks Optimism Among Investors; Here’s Why

Proteostasis Therapeutics (PTI) announced today a worldwide, exclusive license agreement with Genentech for the rights to a potential new therapy, without revealing what …

Tilray (TLRY) Prepares for Mass CBD Oil Purchase Following the Signing of Letter of Intent

The 2018 Farm Bill, which passed Congress is now headed to the desk of President Trump and if he signs it, hemp farms …

MYOS RENS Technology (MYOS) Stock Fires Up to the Roof; Here’s Why

MYOS RENS Technology (MYOS) stock is soaring — up over 50% since news broke today that The Vitamin Shoppe is picking up its product …

A Glimpse Into the Cannabis Stocks’ World

Investing in the marijuana industry may have seemed taboo a few years back, but as more states are making recreational marijuana legal with …

Cartel Investigation Drags Teva Pharmaceutical (TEVA) Stock Down; Evercore Weighs In

Israeli generic drug manufacturer Teva (TEVA) was named by the Washington Post as being one of more than a dozen subjects of a …

Hexindai (HX) Stock Skyrockets on Strategic Investment News

Chinese consumer lending company Hexindai (HX) announced a strategic investment in what it only describes as a “target company” that is well-known in …

Marinus Pharmaceuticals (MRNS) Sparks Optimism Among Investors; Here’s Why

Marinus Pharmaceuticals (MRNS) just released positive results from its Phase 2 clinical trials, which evaluated ganaxolone intravenous (IV) (called the Magnolia Study) and …